Griffiths Ulla K, Miners Alec
Hib Initiative, Health Policy Unit, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
Expert Rev Pharmacoecon Outcomes Res. 2009 Aug;9(4):333-46. doi: 10.1586/erp.09.38.
With the arrival of new, more expensive vaccines, economic evaluation has become an important tool for assessing the feasibility of introducing a new vaccine into a country's routine immunization schedule. Haemophilus influenzae type b (Hib) vaccine has been available since the early 1990s, but uptake of the vaccine was slow in low-income countries until the GAVI Alliance started offering financial support for it. However, at some point, GAVI Alliance-supported countries will have to identify other sources of financing for Hib vaccine, meaning cost-effectiveness evidence will be important to support resource allocation decisions. Several middle-income countries have not yet introduced the vaccine. Thus, the aim of this literature review was to identify and evaluate the published evidence on the cost-effectiveness of the Hib vaccine, with particular emphasis on low- and middle-income countries. It is concluded that there are only few studies available from resource-poor countries and some of these are of low quality.
随着新型、更昂贵疫苗的出现，经济评估已成为评估将新疫苗纳入一国常规免疫计划可行性的重要工具。b型流感嗜血杆菌（Hib）疫苗自20世纪90年代初就已问世，但在低收入国家，直到全球疫苗免疫联盟开始提供资金支持，该疫苗的接种率一直很低。然而，在某个时候，全球疫苗免疫联盟支持的国家将不得不寻找Hib疫苗的其他资金来源，这意味着成本效益证据对于支持资源分配决策将很重要。一些中等收入国家尚未引入该疫苗。因此，本综述的目的是识别和评估已发表的关于Hib疫苗成本效益的证据，特别侧重于低收入和中等收入国家。得出的结论是，资源匮乏国家的相关研究很少，其中一些质量较低。
